A new study supports launch of Phase I clinical trial to test a designer DNA agent — an antisense oligonucleotide that targets a gene called IRF4 — in patients with multiple myeloma.
Click here for original story, Designer DNA therapeutic wipes out cancer stem cells, treats multiple myeloma in mice
Source: ScienceDaily